Boston Scientific Corp Total Liabilities
Boston Scientific Corp total liabilities. Based on the latest financial reports, Boston Scientific Corp (BSX) has total liabilities worth $18.25 Billion USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check asset resilience ratio of Boston Scientific Corp to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Boston Scientific Corp (1991–2025)
Total liabilities of Boston Scientific Corp from 1991 to 2025. This chart illustrates how Boston Scientific Corp's total liabilities have evolved over time, based on quarterly financial data. Explore Boston Scientific Corp (BSX) investment intensity to see how much of total assets are deployed in long-term investments.
Boston Scientific Corp Competitors by Total Liabilities
The table below lists competitors of Boston Scientific Corp ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Kinder Morgan Inc
NYSE:KMI
|
USA | $41.18 Billion |
|
Fubon Financial Holding Co Ltd
TW:2881
|
Taiwan | NT$11.85 Trillion |
|
Barclays PLC
F:BCY2
|
Germany | €1.62 Trillion |
|
Transdigm Group Incorporated
NYSE:TDG
|
USA | $34.84 Billion |
|
Bank of China Limited
F:W8V
|
Germany | €36.35 Trillion |
|
Engie S.A.
PA:ENGI
|
France | €154.17 Billion |
|
Atlas Copco AB Series A
ST:ATCO-A
|
Sweden | Skr93.63 Billion |
|
TC Energy Corp
TO:TRP
|
Canada | CA$83.67 Billion |
Liability Composition Analysis (1991–2025)
This chart breaks down Boston Scientific Corp's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Boston Scientific Corp (BSX) total assets.
Liquidity & Leverage Metrics
Boston Scientific Corp Total Liabilities Ratios Explained
Boston Scientific Corp total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.90 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.71 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.41 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Boston Scientific Corp's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Boston Scientific Corp (1991–2025)
The table below shows the annual total liabilities of Boston Scientific Corp from 1991 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $19.20 Billion | +10.40% |
| 2024-12-31 | $17.39 Billion | +11.44% |
| 2023-12-31 | $15.61 Billion | +4.77% |
| 2022-12-31 | $14.90 Billion | -4.56% |
| 2021-12-31 | $15.61 Billion | +1.01% |
| 2020-12-31 | $15.45 Billion | -7.41% |
| 2019-12-31 | $16.69 Billion | +35.97% |
| 2018-12-31 | $12.27 Billion | +2.02% |
| 2017-12-31 | $12.03 Billion | +5.87% |
| 2016-12-31 | $11.36 Billion | -3.81% |
| 2015-12-31 | $11.81 Billion | +18.28% |
| 2014-12-31 | $9.99 Billion | -2.04% |
| 2013-12-31 | $10.20 Billion | -0.87% |
| 2012-12-31 | $10.28 Billion | +3.49% |
| 2011-12-31 | $9.94 Billion | -8.26% |
| 2010-12-31 | $10.83 Billion | -15.87% |
| 2009-12-31 | $12.88 Billion | -7.65% |
| 2008-12-31 | $13.94 Billion | -13.40% |
| 2007-12-31 | $16.10 Billion | +1.91% |
| 2006-12-31 | $15.80 Billion | +303.63% |
| 2005-12-31 | $3.91 Billion | -5.57% |
| 2004-12-31 | $4.14 Billion | +46.11% |
| 2003-12-31 | $2.84 Billion | +43.07% |
| 2002-12-31 | $1.98 Billion | +1.23% |
| 2001-12-31 | $1.96 Billion | +31.30% |
| 2000-12-31 | $1.49 Billion | -19.26% |
| 1999-12-31 | $1.85 Billion | -39.84% |
| 1998-12-31 | $3.07 Billion | +212.92% |
| 1997-12-31 | $981.60 Million | +64.75% |
| 1996-12-31 | $595.80 Million | +85.03% |
| 1995-12-31 | $322.00 Million | +250.76% |
| 1994-12-31 | $91.80 Million | +20.00% |
| 1993-12-31 | $76.50 Million | +53.00% |
| 1992-12-31 | $50.00 Million | +6.16% |
| 1991-12-31 | $47.10 Million | -- |
About Boston Scientific Corp
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. The company operates in two segments, MedSurg and Cardiovascular. It offers devices to diagnose and treat a range of gastrointestinal conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, SpyG… Read more